Clinical Trials · NCT07287098
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 600
- Start date
- May 2026
- Locations
- 89 sites, 7 countries
- Primary endpoint
- Change from Baseline in Antigen Kiel (Ki-67) Expression